Themis Bioscience GmbH

Industry

  • Pharmaceuticals
    • Vaccines
  • Biotechnology
See more in Biomedtracker

Latest on Themis Bioscience GmbH

Scrip

Valneva Advances New Vaccines Agenda With Top-Line Phase III Chikungunya Data

 
• By John Davis

The COVID-19 pandemic may have sparked fresh interest in vaccines research, but France’s Valneva SE was already developing a suite of vaccines for relatively neglected infectious diseases, and posit

Scrip

Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

 
• By Joseph Haas

Who: Merck & Co./OncoImmune What: Merck & Co. will acquire privately held OncoImmune and its Phase III recombinant fusion protein candidate CD24Fc, while spinning out the rest of the company into a

Scrip

Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

 
• By Mandy Jackson

Merck & Co., Inc. won’t be the first to deliver an antiviral drug or a vaccine to treat or prevent COVID-19, but the company revealed progress during its third quarter earnings call on an antiviral a

Scrip

Merck CEO Stresses Need For ‘Fair Return’ On COVID-19 Interventions

 
• By Anju Ghangurde

Merck & Co., Inc. chairman and chief executive officer Kenneth Frazier took on a host of burning questions, including around the pricing of potential COVID-19 therapeutics and vaccines, and on the re